Bausch + Lomb gives up on glaucoma eye drop hopeful after phase 2 fail
Bausch + Lomb has abandoned its next great hope in glaucoma after the eye drops flunked a phase 2 study.
Read the full articleYou might also wanna read
Bausch + Lomb drug fails in glaucoma, but a new use beckons
Bausch + Lomb drug fails in glaucoma, but a new use beckons Phil.Taylor Fri, 10/07/2026 - 09:52
BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure
After 28 days of treatment, BL1107 did not meet its main goal of improving visual field scores in a study.
Life Biosciences Conducts First Gene Therapy Trial to Reverse Cellular Aging in Patient with Glaucoma
For the first time ever, scientists are attempting to reverse cellular aging in a living patient. The target: incurable vision loss. The ris
popularmechanics.com·14d ago
Researchers Develop Experimental 'Living Eye Drops' Using Engineered Bacteria to Heal Corneas
Researchers engineered living eye drops using bacteria to heal the cornea with one application. Here is how the experimental therapy could t
bit.ly·24d agoDorzolamide/Brimonidine/Timolol Impact on Ocular Surface, Glaucoma Progression & Chatbot Follow-up: GLAUCO-TECH
Conditions : Primary Open-Angle Glaucoma (POAG); Ocular Hypertension Interventions : Combination Product: Preservative-free dorzolamide-timo
Eye Drops Show Promise as Alternative to Glasses and Surgery for Presbyopia
Research shows most patients can read extra lines on eye test charts after twice-daily treatment
theguardian.com·9mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.